Skip to main content
. 2017 Feb 7;5(4):143–164. doi: 10.2217/ijh-2016-0011

Table 4. . IDH inhibitors at various stages of clinical development.

Inhibitor Structure Specificity Dosing (mg) Clinical studies Company
AG-120 (Ivosidenib) graphic file with name ijh-05-143-T4a.gif IDH1 100–500 (b.i.d.)
500–1200 (q.d.)
500 for Phase II studies		 Phase I/II Agios Pharmaceuticals Inc.
AG-221 (Enasidenib) graphic file with name ijh-05-143-T4b.gif IDH2 30–150 (b.i.d.)
50–450 (q.d.)
100 for Phase II studies		 Phase I/II Agios Pharmaceuticals Inc.
AG-881 N.A. IDH1/IDH2 5–100 (q.d.) Phase I Agios Pharmaceuticals Inc./Celgene
IDH305 N.A. IDH1   Phase I Novartis

b.i.d.: Twice per day; N.A.: Not available; q.d.: Once per day.